Presenter: William E. Boden, MD, Professor of Medicine and Public Health, University of New York at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York A trial called Clinical Outcomes utilizing Revascularization and Aggressive DrufEvaluation (COURAGE) attempted to determine whether adding PCI to optimal medical therapy would reduce death, MI, or hospitalizations among patients [...]

As the lead investigator of the Thrombin iteceptor Antagonist in Percutaneous Coronary intervention (TRA-PCI) trial, Dr. Moliterno also took up the recurring theme that for patients undergoing PCI, new agents intended to further reduce clinical events without adding a tendency to cause bleeding have been elusive so far.

Presenter: John R. Crouse III, MD, Wake Forest University School of Medicine, Winston-Salem, North Carolina In ASTEROID (AStudy To Evaluate the effect of Rosuvastatin On intravascular ultrasound-Derived coronary atheroma burden), measuring carotid artery intima media thickness (CIMT) with intravascular ultrasound (IVUS) was a reliable means of assessing atherosclerosis, itself a predictor of the risk for [...]

Pre-treatment with High-Dose Statins: Improved Outcomes for Acute Coronary Syndrome Presenter: Germano Di Sciascio, MD, Campus Bio-Medico University, Rome, Italy In patients with acute coronary syndrome (ACS) who undergo early invasive percutaneous coronary intervention (PCI), giving high-dose statins for a short term may improve outcomes.